Article No
BPS-79694
Cells
Anti-BCMA CAR Jurkat/NFAT (Luciferase) Reporter Cell Line
Anti-BCMA CAR Jurkat/NFAT (Luciferase) Reporter Cell Line
Specifications
| Additional Information | License Disclosure_x005F_x000D_ Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS products to your laboratory. BPS does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact support@nordicbiosite.com for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego. |
| Article No | BPS-79694 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT, RU |
| Description | Anti-BCMA CAR Jurkat/NFAT (Luciferase) Reporter Cell Line |
| Supplier | BPS Bioscience |
| Notes | The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a stable cell line made from the anti-BCMA scFV CAR lentivirus (BPS Bioscience #79701). It has been validated for anti BCMA-CAR expression by FACS, and for functional activation stimulated by both soluble BCMA protein (BPS Bioscience #79467) and BCMA/CHO target cells (BPS Bioscience #79500). |
| Alias Names | tumor necrosis factor receptor superfamily member 17, B-Cell Maturation Antigen, TNFRSF17, CD28, T-cell receptor zeta, 4-1BB, CD137 |
| Product Type | Cells |
| References | 1. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. Wang et. al. J Hematol Oncol. 2019 Jun 11;12(1):592. Chimeric antigen receptor T cell therapy for multiple myeloma. Hasegawa et.al. Inflamm Regen. 2019 Jun 4;39:10.3. Novel targets for the treatment of relapsing multiple myeloma. Giuliani et. al. Expert Rev Hematol. 2019 Jun 3:1-16.4. Anti-BCMA antibodies in the future management of multiple myeloma. Gavriatopoulou et. al. Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326. |
| Shipping Information | DRY ICE |
| Size | 2 vials |
| Storage | LIQUID NITROGEN |
| Substrate / Buffer | Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO and 90% FBS |
| Technical Specifications | • Predict the MOA of the CAR design • Measurements of antibody (scFV-CAR) specificity • Screen and validate BCMA-expressing caner target cells |
| Product Page Updated | 2021-01-05T12:59:29.990Z |
Shipping info
The delivery time for this item is approximately 5-8 business days.
If other deviations occur, this will be noted on the order confirmation or communicated via email.
Please note, we do reserve the right to select the best packaging and shipping method in order to insure the stability of the product and allow efficient order tracking.